Reports Q2 revenue $300K, consensus $530K. Cash, cash equivalents and marketable securities as of June 30, 2023 were $252.7M compared to $278.4M as of March 31, 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CLDX:
- Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
- Celldex completes enrollment in Phase 2 study of barzolvolimab
- Celldex doses first patient in Phase 2 study of barzolvolimab
- Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
- 3 Best Stocks to Buy Now, 6/12/2023, According to Top Analysts